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Mice carrying a truncated form of cAMP-responsive element bind-
ing protein (CREB)-binding protein (CBP) show several develop-
mental abnormalities similar to patients with Rubinstein–Taybi
syndrome (RTS). RTS patients suffer from mental retardation,
whereas long-term memory formation is defective in mutant CBP
mice. A critical role for cAMP signaling during CREB-dependent
long-term memory formation appears to be evolutionarily con-
served. From this observation, we reasoned that drugs that mod-
ulate CREB function by enhancing cAMP signaling might yield an
effective treatment for the memory defect(s) of CBP/ mice. To
this end, we designed a cell-based drug screen and discovered
inhibitors of phosphodiesterase 4 (PDE4) to be particularly effec-
tive enhancers of CREB function. We extend previous behavioral
observations by showing that CBP/ mutants have impaired
long-term memory but normal learning and short-term memory in
an object recognition task. We demonstrate that the prototypical
PDE4 inhibitor, rolipram, and a novel one (HT0712) abolish the
long-term memory defect of CBP/ mice. Importantly, the genetic
lesion in CBP acts specifically to shift the dose sensitivity for HT0712
to enhance memory formation, which conveys molecular specific-
ity on the drug’s mechanism of action. Our results suggest that
PDE4 inhibitors may be used to treat the cognitive dysfunction of
RTS patients.
Rubinstein–Taybi syndrome (RTS) is a human genetic disor-der characterized by mental retardation and physical abnor-
malities including broad thumbs, big and broad toes, short
stature, and craniofacial anomalies (1–3). RTS occurs in about
1 in 125,000 births and accounts for as many as 1 in 300 cases of
institutionalized mentally retarded people. In many patients,
RTS has been mapped to chromosome 16p13.3, a genomic
region containing cAMP-responsive element binding protein
(CREB)-binding protein (CBP) (4). Many RTS patients are
heterozygous for CBP mutations that yield truncations of the
CBP C terminus, suggesting that a dominant-negative mecha-
nism may contribute to the clinical symptoms (5).
CBP is a transcriptional coactivator that binds to the CREB
transcription factor when the latter is phosphorylated (6).
CREB-dependent gene expression has been shown to underlie
long-term memory formation in several vertebrate and inverte-
brate species (7–12), leading to the intriguing speculation that
mental retardation in RTS patients may derive from reduced
CBP function during long-term memory formation (13, 14). To
this end, Oike et al. (15) generated a C-terminal truncation
mutation in mouse CBP, which appears to act in a dominant-
negative fashion to recapitulate many of the abnormalities
observed in RTS patients. Homozygous CBP/ mutants are
embryonic lethal, whereas heterozygous CBP/ mice show
reduced viability, growth retardation, retarded osseous matura-
tion, and hypoplastic maxilla (15). Importantly, CBP/ mice
show normal learning and short-term memory (STM) but de-
fective long-term memory (LTM) for two passive avoidance
tasks, substantiating the notion that normal CBP function is
required for memory formation (15).
These studies demonstrate that CREBCBP likely function
together as a molecular switch during long-term memory for-
mation. Because CREBCBP function is reduced but not elim-
inated in CBP/ mutant mice, the possibility existed to improve
long-term memory formation by enhancing upstream signaling
onto CREBCBP. Here, we demonstrate that inhibitors of
phosphodiesterase 4 (PDE4) (i) enhance CREB-dependent
gene expression and (ii) ameliorate the long-term memory
defects of CBP/ mutant mice in a dose-dependent manner,
which differs between normal and mutant mice.
Methods
The Mice. Generation of CBP/ mice was described by Oike et
al. (15). For these studies, we bred animals by crossing CBP/
males to C57BL6 females (The Jackson Laboratory). The mice
were genotyped with a PCR protocol as described (15). We
found CBP/ mutants to be subviable. Only 25 of 168 progeny
were heterozygous; this observed frequency (15%) is apprecia-
bly below that expected (50%) from the cross if wild-type and
heterozygous animals were equally viable. Age-matched (12–14
weeks old by the time of handling) and gender-matched mutant
mice and wild-type littermates were used for all experiments.
The mice were kept on a 12:12 lightdark cycle, and the
experiments were conducted during the light phase of the cycle.
With the exception of training and testing times, the mice had ad
lib access of food and water. The experiments were conducted
according to Animal Welfare Assurance no. A3280-01, and
animals were maintained in accordance with the Animal Wel-
fare Act and the Department of Health and Human Service
guide.
Object Recognition Training and Testing. Mice were handled for 3–5
min for 5 days. The day before training, an individual mouse was
placed into a training apparatus (a Plexiglas box 48 cm long, 38
cm wide, and 20 cm high, located in a dimly lit room) and allowed
to habituate to the environment for 15 min (also see ref. 16).
Training was initiated 24 h after habituation. A mouse was
placed back into the training box, which contained two identical
objects (e.g., a small conus-shape object), and was allowed to
explore these objects. The objects were placed into the central
area of the box, and the spatial position of objects (left–right
sides) was counterbalanced between subjects. Among experi-
ments, training times varied from 3.5 to 20 min.
We used four separate, and otherwise experimentally naı¨ve,
sets of animals. The first set was used for the experiment
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summarized in Fig. 2 A (wild-type mice, n  20). The second set
was used for experiments summarized in Fig. 2 B and C (n  10
per genotype). The third set was used for the experiment
summarized in Fig. 3A (wild-type mice, n  20). The fourth set
was used for the experiment summarized in Fig. 3B (n  8 per
genotype). For each experiment, the same set of animals was
used repeatedly with different (new) sets of objects for each
repetition. Five to nine repetitions were performed on each set
of mice. Each mouse was trained and tested no more than once
per week and with a 1-week interval between testing. In exper-
iments with drug-injections (see below), vehicle-injected mice
and highlow-dose-injected mice were counterbalanced. All
experiments were designed and performed in a balanced fashion,
meaning that (i) for each experimental condition (e.g., a specific
dose-effect andor genotype-memory effect) we used two to six
experimental mice and two to six control mice; (ii) experiments
with HT 0712 injections always consisted of the vehicle-injected
mice and mice injected with two to three different doses of HT
0712; (iii) each experimental condition was replicated two to
four independent times, and replicate days were added to
generate final number of subjects. In each experiment, the
experimenter was unaware (blind) to the treatment of the
subjects during training and testing.
To test for memory retention, mice were observed for 10 min
3 and 24 h after training. Mice were presented with two objects,
one of which was used during training, and thus was ‘‘familiar,’’
and the other of which was novel (e.g., a small pyramid-shape
object). The test objects were divided into 10 sets of two
‘‘training’’ plus ‘‘testing’’ objects, and a new set of objects was
used for each training session. To ensure that the discrimination
targets did not differ in smell, after each experimental subject,
the apparatus and the objects were thoroughly cleaned with 90%
ethanol, dried, and ventilated for a few minutes.
Drug Compound Administration. Twenty minutes before training,
mice were injected in their home cages with the indicated doses
of HT 0712, Rolipram (in 1% DMSOPBS) or with vehicle alone
(1% DMSOPBS). HT0712 was administered i.p. at doses of
0.001, 0.005, 0.01, 0.05, 0.10, 0.15, 0.20, and 0.50 mgkg. Roli-
pram was administered i.p. at 0.10 mgkg. Drug compounds
were injected with 1-week intervals to allow for sufficient
wash-out time (the half-life for HT 0712 and Rolipram3 h). In
addition, vehicle- and drug-injected mice were counterbalanced
from experiment to experiment. Such design allowed at least a
2-week wash-out time between repeated usages of high doses.
We have not observed any dose-accumulating effects with
repeated injections betweenwithin the groups (data not
shown).
Data Analysis. The experiments were videotaped via an overhead
video camera system. Types were reviewed by a blinded observer
and the following behavioral parameters were determined: time
of exploration of each object, the total time of exploration of the
objects, number of approaches to the objects, and time (latency)
to first approach an object. The discrimination index (DI) was
determined as the difference in exploration time expressed as a
ratio of the total time spent exploring the two objects in the
choice (testing) phase (17). This ratio serves to normalize for
individual or group differences in the total amount of explora-
tion time. Data were analyzed by Student’s unpaired t test using
a software package (STATWIEW 5.0.1, SAS Institute, Cary, NC).
All values in the text and figures are expressed as mean  SEM.
CRE-Luciferase Assay. A cell-based screening system was devel-
oped with a functional read-out of CREB-dependent transcrip-
tion. Ten thousand SK-N-MC neuroblastoma cells, stably trans-
fected with a reporter construct consisting of the VIP promoter
containing two CRE elements together with two additional
CRE elements from the tyrosine aminotransferase gene driving
expression of luciferase, were plated in a 96-well plate format
overnight at 37°C. The next day, cells were incubated with drug
(5 M) or vehicle (0.2% DMSO) for 2 h, after which forskolin
(5 M) was added to the cells. After a further 6-h incubation at
37°C, cells were washed briefly with PBS and lysed, and lucif-
erase activity was measured by using a Victor 5 luminometer.
Real-Time Quantitative PCR. Drugs were tested for their ability to
superinduce the endogenous CREB-responsive gene Somatosta-
tin in the neuroblastoma SK-N-MC cell line. A total of 500,000
cells (in triplicate for each condition) were plated in a 96-well
plate format and incubated overnight at 37°C. Cells were incu-
bated for 2 h with drug (5 M) or vehicle (0.2% DMSO),
followed by a 6-h incubation with forskolin (5 M). Cells were
washed twice with cold PBS, and RNA was isolated. Somatosta-
tin RNA levels were examined by real-time quantitative PCR
using an Applied Biosystems 7900 real-time PCR instrument for
rapid RNA analysis. Somatostatin RNA levels were normalized
against TFIID (TATA-binding protein) RNA levels.
Results
PDE4 Inhibitors Increase CREB-Dependent Gene Expression. A high-
throughput drug screen was conducted by using human SK-
N-MC neuroblastoma cells, which were stably transfected with a
luciferase reporter gene driven by a CRE promoter (18). Cells
were exposed to drug for 2 h and then stimulated with a
suboptimal dose of forskolin for further 6 h. Compounds were
identified that had no effect on their own but that significantly
increased forskolin-induced CRE-luciferase expression. Among
the dozens of confirmed active compounds for several molecular
targets identified from this screen, inhibitors of PDE4 were
numerous. Consequently, we focused our attention on a novel
PDE4 inhibitor, HT 0712. In addition, we also studied Rolipram,
a prototypical PDE4 inhibitor that has been shown previously to
affect performance in animal models of memory (19–21). Both
compounds produced robust effects on CRE-luciferase expres-
sion and on expression of a CRE-dependent endogenous gene,
somatostatin (Fig. 1).
Long-Term Memory for Object Recognition Is Defective in CBP/
Mutant Mice. Our initial experiments on normal, young-adult
mice established that long-term memory formation after con-
textual fear conditioning was enhanced by HT0712 and rolipram,
delivered directly to the hippocampus, intraventricularly, or i.p.
(refs. 7 and 18 and data not shown). Specifically, these drugs
enhance memory formation by reducing the amount of training
required to produce maximal long-term memory. We also were
interested to determine whether these drugs could ameliorate
memory defects caused by molecular lesions in the CREB
pathway. The mouse model of RTS was particularly attractive
because (i) the molecular lesion (truncated protein) in mice was
similar to those known for some RTS patients, (ii) CBP function
in CBP/ heterozygous mice was reduced but not blocked, and
(iii) long-term memory formation, but not learning or short-term
memory, appeared specifically to be disrupted in these mutant
animals (15).
Long-term memory defects in CBP/ mutant mice have been
reported only for fear-based tasks (15). Hence, we first wanted
to know whether CBP/ mutant mice also had defective
long-term memory for a different type of experience. Object
recognition is a nonaversive task that relies on a mouse’s natural
exploratory behavior. During training for this task, mice are
presented with two identical novel objects, which they explore
for some time by orienting toward, sniffing, and crawling over.
Normal mice then will remember having explored that object. To
test for this memory, mice are presented at a later time with two
different objects, one of which was presented previously during
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training and thus is ‘‘familiar,’’ and the other of which is novel.
If the mouse remembers the familiar object, it spends more time
exploring the novel object. By analogy to an object recognition-
based ‘‘nonmatching to sample’’ task in monkeys and rats (22,
23), this task can be performed repeatedly on the same animals
by exposing them serially to different sets of novel objects.
Compared with fear-based tasks, which use relatively strong
punishment as reinforcement, object recognition is considered
to be a poorly motivated task. One consequence is appreciable
interstrain variation in performance. Hence, we calibrated our
training protocol for the genetic background represented by the
wild-type (normal) littermates of CBP/ mutant mice. Initially,
we subjected these wild-type mice to various durations of
training, ranging from 3.5 to 20 min and then quantified 1-day
memory thereafter. Maximal 1-day memory was reached with a
15- or 20-min training duration, whereas no 1-day memory was
detected with a 3.5-min training duration (Fig. 2 A).
We then gave CBP/ mutants and their wild-type littermates
15 min to explore novel objects during training and tested their
memory retention 3 and 24 h later (Fig. 2B). Three-hour
memory appeared normal, but 1-day memory was abnormally
low, in CBP/ mutants (DI  34  7 and 1  7 for wild-type
mice and CBP/ mutants, respectively; P 0.01]. These results
indicate that CBP/ mutant mice have impaired long-term
Fig. 2. Object recognition memory in CBP/ mutant mice and their normal
siblings. (A) One-day memory retention in object recognition depends on
duration of training. Wild-type mice were subjected to a 3.5-min (n  24),
5-min (n  24), 8-min (n  16), 15-min (n  46), or 20-min (n  12) training
duration and then tested 24 h later. Memory retention was quantified as a DI
(see Methods). Maximal memory retention was reached with a training du-
ration of 15 min. In contrast, 1-day memory was not detected after a 3.5-min
training duration. (B) CBP/ mutant mice have impaired long-term memory
of an object recognition task. Wild-type mice and CBP/ mutant mice were
trained for 15 min and tested 3 h or 24 h later. Three-hour memory levels were
similar for normal mice and CBP/ mutants (P  0.76; n  6 for each
genotype), but 24-h memory was significantly lower than normal in mutant
mice (P 0.01; n 10 for each genotype). (C) PDE4 inhibitors ameliorate the
long-term memory defect of CBP/ mutant mice. Wild-type mice and CBP/
mutant mice received i.p. injections of 0.1 mgkg HT 0712 or Rolipram 20 min
before training. Animals were trained with a 15-min training session, and mem-
ory retention was tested 24 h later (see Methods). In vehicle-injected CBP/
mutants, memory was significantly lower than in vehicle-injected wild-type mice
(P  0.01; n  12 and n  6, respectively). In HT0712-injected CBP/ mutants,
memory was significantly higher than in vehicle-injected mutants (P 0.05, n
10 and n  12, respectively). Similarly, memory retention in Rolipram-injected
animals was significantly higher than that in vehicle-alone-treated animals (P
0.05; n8 and n12, respectively). There was no significant difference between
HT0712-treated CBP/mutants and HT0712-treated wild-type mice (P0.78) or
between Rolipram-treated CBP/mutants and Rolipram-treated wild-type mice
(P 0.19). N values reflect number of observations (repetitions) per treatment.
Fig. 1. PDE4 inhibitors enhance forskolin-induced gene expression in human
neuroblastoma cells. (A) Cells were stably transfected with a CRE-luciferase
reporter gene and exposed to vehicle alone or drug (HT0712 or rolipram) for
2 h before stimulation by a suboptimal dose of forskolin. Relative light units
(RLU) emitted from luciferase were quantified. Both drugs increased forsko-
lin-induced CRE-luciferase expression 1.9-fold above forskolin alone (P 
0.001 in each case). (B) Real-time PCR was used to quantify expression of
somatostatin, an endogenous cAMP-responsive gene. Expression levels in-
duced by forskolin or by forskolin plus drug are quantified as differences in
threshold cycle number (Ct) above vehicle alone control groups (not shown).
HT0712 and rolipram produced 4.6-fold (P  0.001) and 2.3-fold (P  0.001)
increases, respectively, in forskolin-induced expression of somatostatin.
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memory, but normal short-term memory, for object recognition
under training conditions that yield maximal 1-day memory in
normal mice of the same genetic background. These findings
extend the observations of Oike et al. (15) to an ethologically
relevant, nonaversive behavior and confirm the notion that
loss-of-function mutations in CBP can yield specific defects in
long-term memory formation.
PDE4 Inihibitors Ameliorate the Long-Term Memory Deficit of CBP/
Mutant Mice in a Dose-Dependent Manner. To evaluate the PDE4
inhibitors, drug or vehicle alone were administered i.p. to normal
mice and CBP/ mutants 20 min before a 15-min training
session (Fig. 2C). As in the previous experiment, 1-day memory
retention was significantly reduced in CBP/ mutants treated
with vehicle alone (DI  9  7; P  0.01). In striking contrast,
however, a single administration of 0.10 mgkg HT0712 or
Rolipram restored 24-h memory to normal levels in CBP/
mutants (DI  40  5 and 32  6 for HT 0712 and Rolipram
treated mice, respectively).
To address whether the drugs’ effects were specific to the
molecular lesion in CBP, we changed our training protocol and
determined dose sensitivity curves for mutant and wild-type
animals. Our 15-min training protocol produces maximum 1-day
retention in the wild-type mice used here (Fig. 2 A). Conse-
quently, we did not see any drug-induced memory enhancement
in wild-type mice (Fig. 2C). By reducing training to a 3.5-min
protocol, however, 1-day retention was near zero in wild-type
mice, thereby allowing an evaluation of the enhancing effects of
the PDE4 inhibitors. We then reasoned that, because CBP/
mutants had less functional CBP than wild-type animals, a higher
concentration of drug might be required in the mutants than in
wild-type mice to produce equivalent levels of memory enhance-
ment. In essence, the molecular lesion in CBP would act spe-
cifically to shift the dose sensitivity for a PDE4 inhibitor to
enhance memory formation, a concept advanced by Silva and
coworkers (24).
We first quantified the dose–response curve for wild-type
mice (Fig. 3A). In mice treated with vehicle alone, the 3.5-min
training protocol did not produce any appreciable 1-day mem-
ory. At concentrations below 0.05 mgkg or above 0.20 mgkg,
HT 0712 failed to produce any memory enhancement. One-day
memory retention was significantly increased, however, at
HT0712 concentrations of 0.05, 0.10, 0.15, and 0.20 mgkg. Next,
we compared memory retention between CBP/ mutants and
wild-type animals at selected concentrations of HT0712 (Fig.
3B). We found that the initial effective dose differed between
mutant and wild-type animals. Again, at a dose of 0.05 mgkg,
wild-type animals showed significant enhancement of 1-day
memory (21  6 vs. 2  4; HT0712- and vehicle-treated mice,
respectively; P  0.005), but CBP/ mutants did not. Memory
enhancement was first seen in CBP/mutants at the next higher
dose of HT0712 (0.10 mgkg; 32  12 vs. 7  4 for HT0712-
and vehicle-treated mice, respectively, P 0.0001). Similarly, the
peak effective dose appears shifted to a higher concentration in
mutants (0.15 mgkg) than in wild-type mice (0.10 mgkg).
We considered whether HT 0712 might be increasing perfor-
mance in our task nonspecifically by affecting perception of the
training context (objects) or the motivation to explore objects
during training or testing. We analyzed the latency to first
approach an object during training, the total number of ap-
proaches to an object, and the total exploration time. In all
experiments, no differences between genotypes andor drug
treatments were observed in the latency to first approach (data
not shown). CBP/ mutant mice showed increases in total
exploration time and in the total number of object-approaches,
but drug treatments did not change these measures, and these
behavioral responses were not correlated with DIs (data not
Fig. 3. HT0712 dose sensitivity is decreased in mutant CBP/ mice. (A)
Dose–response curve for HT 0712 in wild-type mice. Mice received a single i.p.
injection of drug or vehicle alone 20 min before training. Doses of 0.001, 0.005,
0.01, 0.05, 0.10, 0.15, 0.20, and 0.5 mgkg were used. Animals experienced a
3.5-min training duration and were tested 24 h later (see Methods). Memory
retention in drug-injected animals was significantly higher than that in vehi-
cle-alone treated animals (n  35) at doses of 0.05 mgkg (n  20; P  0.05),
0.10 mgkg (n  22; P  0.0001), 0.15 mgkg (n  18; P  0.001), and 0.20
mgkg (n  17; P  0.05). There were no significant effects at doses 0.001
mgkg (P 0.91; n 6 for HT0712), 0.005 mgkg (P 0.72; n 22 for HT0712),
or 0.01 mgkg (P  0.34; n  10 for HT0712). Because each session included
vehicle-injected mice, the data for vehicle-injected mice were pooled. N values
indicate a number of observations (repetitions) per treatment. (B) CBP/
mutant mice are less sensitive than wild-type mice to the enhancing effects of
HT 0712. CBP/ mutants and wild-type mice received a single i.p. injection of
vehicle or drug 20 min before training. They experienced a 3.5-min training
duration and were tested 24-h later (see Methods). In wild-type mice, memory
retention in drug-treated groups again was higher than in the vehicle-alone
group (n 26) at doses of 0.05 mgkg (n 12; P 0.005), 0.10 mgkg (n 8;
P 0.0001), 0.15 mgkg (n 18; P 0.005), and 0.2 mgkg (n 14; P 0.005).
In CBP/mutants, memory retention in drug-treated groups was higher than
in the vehicle-alone group (n 26) at doses of 0.10 mgkg (n 8; P 0.0001),
0.15 mgkg (n  10; P  0.0001), and 0.20 mgkg (n  14; P  0.0001). In
contrast to wild-type mice, a 0.05 mgkg dose of HT0712 failed to enhance
memory (n  26; P  0.79) in CBP/ mutants. N values reflect number of
observations (repetitions) per dose per genotype.
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shown). Similarly, we did not observe any behavioral side effects
(lethargy, nausea, etc.) from any doses of HT0712.
We also administered HT0712 immediately after training to
dissociate further any possible nonspecific effects on perfor-
mance from its more specific effect on memory consolidation.
Mutant and wild-type mice were trained and then injected with
0.15 mgkg HT0712 or vehicle immediately thereafter. Again, we
observed significant memory enhancement 1 day after training
in both CBP/ mutant mice (23 5 vs.5 3 for HT0712- vs.
vehicle-treated mice; n  12 and n  8, respectively; P  0.001)
and wild-type mice (22  5 vs. 9  9 for HT0712- vs.
vehicle-treated mice; n  12 and n  8, respectively; P  0.01).
Finally, the 3.5-min training protocol did not produce signif-
icant short-term memory, tested 1 h after training, and HT 0712
did not have any appreciable memory-enhancing effects on
short-term memory (n 6 per genotype; data not shown). These
observations support our previous findings (19), where Rolipram
had no effect on short-term memory for fear conditioning. They
also are in agreement with the functional role of CREB in
memory formation, namely, its requirement for long-term, but
not for short-term, memory.
Discussion
Our data indicate that the memory impairments observed for
CBP/ mutants in an object recognition task can be amelio-
rated by inhibitors of PDE4. These PDE inhibitors likely en-
hance signaling to CREB during memory formation by increas-
ing cAMP levels in response to experience-dependent changes in
neural activity (18–20, 25). This effect apparently is specific
molecularly, because CBP/ mutants require a higher dose of
HT0712 than wild-type mice to produce an equivalent amount of
enhanced memory. This result, in fact, might be expected
because the genetic lesion of CBP/ mutant mice likely reduces
the amount of CREBCBP available for functional activation via
cAMP signaling. Hence, greater upstream enhancement is re-
quired for a comparable effect on the regulation of downstream
genes (see ref. 8). Given that CBP interacts with several tran-
scription factors (26–28), likely via an innate histone acetyltrans-
ferase activity (29, 30), our results strongly suggest CREBCBP
to be the relevant interaction for long-term memory formation.
Because of the observed molecular and pathological similarities
between these CBP/ mice and patients with RTS, we hypoth-
esize that the mental retardation of RTS patients likely results,
at least in part, from defects in long-term memory formation.
Further, PDE4 inhibitors may ameliorate this biochemical block
on memory formation, thereby rendering the patient capable to
benefit from training and experience.
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